Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol.
Julia C GreenlandEmma CuttingSonakshi KadyanSimon BondAnita ChhabraCaroline H Williams-GrayPublished in: BMJ open (2020)
ISRCTN14616801 and EudraCT- 2018-003089-14.